Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00943917 · ClinicalTrials.gov registry record · Phase 2
Study of ITCA 650 (Exenatide in DUROS) in Subjects With Type 2 Diabetes Mellitus
A Phase 2 study, sponsored by Intarcia Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 155
- Enrollment target
NCT00943917 is a Phase 2 study that has completed, run by Intarcia Therapeutics. The registered enrollment target is 155 participants.
The verdict
NCT00943917, a Phase 2 study, has completed, sponsored by Intarcia Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 155 participants
- Enrollment target
Study Summary
The purpose of this study is to determine safety, efficacy and tolerability of various doses of ITCA 650 in subjects with type 2 diabetes.
Interventions
- DRUG Exenatide Injection
- OTHER ITCA 650
- OTHER Ex Inj/ITCA 650
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 155 participants |
| Start Date | 2009-08 |
| Est. Completion | 2011-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00943917
The ClinicalTrials.gov registry entry for NCT00943917 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 155 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Intarcia Therapeutics, which has 16 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Exenatide Injection is the first listed.
NCT00943917 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00943917 about?
NCT00943917 is a clinical study titled "Study of ITCA 650 (Exenatide in DUROS) in Subjects With Type 2 Diabetes Mellitus". The purpose of this study is to determine safety, efficacy and tolerability of various doses of ITCA 650 in subjects with type 2 diabetes.
What is the current status of trial NCT00943917?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 155 participants. The study started on 2009-08. Estimated completion is 2011-02.
What interventions are being tested in trial NCT00943917?
The interventions under investigation include: Exenatide Injection (DRUG), ITCA 650 (OTHER), Ex Inj/ITCA 650 (OTHER).
Who is sponsoring clinical trial NCT00943917?
This trial is sponsored by Intarcia Therapeutics, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.